Plasma Biomarkers in Diverse Populations

Abstract

Background: Recent advancements in plasma biomarkers, particularly p ‐tau217, have highlighted its potential for early Alzheimer's Disease (AD) detection. p ‐tau217 demonstrates diagnostic accuracy comparable to amyloid PET and cerebrospinal fluid (CSF) tests, with strong sensitivity and specificity to Aβ PET and tau PET results.